Skip to main content

Long-term prognosis analysis of PARACHUTE device implantation in patients with ischemic heart failure: a single-center experience of Chinese patients

Abstract

Background

Heart failure (HF) is one of the leading causes of mortality and morbidity. The PARACHUTE device is designed to partition for left ventricular (LV) apical aneurysm post extensive anterior myocardial infarction (MI). However, the long-term prognosis of the PARACHUTE device post-implantation is unclear.

Methods

From November 2015 to April 2017, six subjects with New York Heart Association Classes II, III and IV ischemic HF, LV ejection fraction between (LVEF) 15 and 40%; and LV anterior apical aneurysm were enrolled in our center. The cumulative event rates for MI, hospitalization, and mortality were documented. Further assessment of LVEF, LV end-diastolic diameter (LVEDD), and estimated pulmonary artery pressure were determined by echocardiography core laboratory. For quantitative data comparison, paired t-test was employed.

Results

Device implantation was successful in all six enrolled subjects, and acute device association adverse events were not observed. At 4.6 ± 1.7 years follow-up, major adverse cardiac events (MACEs) were found in 50% patients, and the survival rate was 86.7%. We observed that the LVEF was significantly elevated after deployment (46.00 ± 6.00% vs. 35.83 ± 1.47%, P = 0.009). Besides, the LVEDD elevated after MI (51.17 ± 3.71 vs. 62.83 ± 3.25, P < 0.001) was revealed, but the device sustained preserved LVEDD after implantation.

Conclusion

The PARACHUTE device is an alternative therapy for patients with severe LV maladaptive remodeling. However, the device seems to increase the HF ratio.

Trial registration

NCT02240940

Peer Review reports

Introduction

Left ventricle (LV) maladaptive remodeling after acute myocardial infarction (MI) has been well documented in experimental and clinical trials [1, 2]. During the past decades, the number of hospitalizations for acute MIs has increased significantly. Despite the treatment improvement in MI, the long-term prognosis of MI-related LV remodeling remains unfavorable.

The concept of percutaneous ventricular restoration (PVR) therapy of dilated LV is based on the premise of a dedicated partitioning device for LV volume reduction and geometric reconfiguration [3,4,5]. PARACHUTE® (CardioKinetix, Redwood City, CA, USA) is the first device designed for PVR, and it minimizes the risk of other invasive methods.

Previous clinical trials implied that the PARACHUTE device may reduce cardiac dimensions and end-diastolic wall stress, thereby benefitting patients with LV dilation post-MI. However, little is known about the long-term cardiac function, life quality, and major adverse cardiac events (MACEs) of PARACHUTE-implanted patients.

Therefore, we retrospectively collected the clinical and average 4.6 years follow-up data to analyze the PARACHUTE device-related outcomes and complications, and we also performed a per- versu post-implantation pairwise comparison of patients’ echocardiography parameter. In addition, we investigated the potential factor of an adverse event in these patients.

Methods

Study design and patient selection criteria

The Percutaneous Ventricular Restoration in Chronic Heart Failure due to Ischemic Heart Disease (PARACHUTE) China (NCT02240940, https://clinicaltrials.gov/ct2/show/NCT02240940) is a prospective, non-randomized observational study designed to assess the safety and efficacy of the PARACHUTE device. Clinical and echocardiographic follow-up was performed.

Inclusion criteria were as follows: enrolled cases were patients with symptomatic ischemic HF with NYHA Classes II, III, and IV. These patients were 18–75 years old with LV motion abnormalities secondary to anterior MI. LVEF ranged from 15 to 40%, which was measured by the 2D echocardiography core laboratory (core lab). All participants with myocardial ischemia underwent revascularization and received optimal and standard HF medical therapy for at least 3 months before enrollment.

The exclusion criteria were as follows: significant valvular stenosis or regurgitation, chronic obstructive pulmonary disease, end-stage renal disease requiring hemodialysis, cerebral vascular accident, or transient ischemic attacks occurring within 6 months. Selected computed tomography (CT) was applied for proper device size selection. All sites obtained approval from the Ethics Committee before the study began, and written informed consent was obtained for all patients at the appropriate time before involvement in this study. After the implantation of the device, clinical and echocardiographic follow-up was performed annually for up to 3 years.

Study device and procedure

Details of the device and procedure had been previously published [3,4,5]. In brief, the procedure was performed in a catheterization laboratory with the patients usually under conscious sedation. Multi-slice CT (Supplementary Figure 1) was implemented to provide accurate measurements and rule out LV apical thrombus, pseudochorda, or severe calcification. After the expansion of the device, the occlusive membrane provides a barrier to seal off the static chamber on the distal side of the device. All patients received low-dose aspirin and anticoagulation with warfarin for at least 12 months of post-device implantation.

Transesophageal echocardiography

Patients underwent 3D-transthoracic echocardiography (TTE) and 2D-TEE with IE-33 Philips systems (Andover MA, USA) by using a 3D X5–1 PureWave matrix-array transducer. Images were digitally acquired for off-line reconstruction (for 3D-TEE images) and interpretation. 2D-TEE was used from basal to mid-esophageal levels.

Date collection and follow-up

All study-related data were collected on standardized case report forms [3,4,5] We assessed the successful delivery and deployment of the PARACHUTE device. The average of 4.6 years of follow-up data on MACEs was recorded. MACEs were defined as cardiac death, emergent cardiac surgery, cardiac tamponade, peripheral embolization, new or worsening HF, endocarditis or device infection, device migration or embolization. We collected echocardiography measurements, including LV end diastolic diameter (LVEDD), LLVEF, and estimated pulmonary artery pressure (PAP). Functional parameters such as NYHA functional class ranking were also determined. Data management was performed by contract research organization, and adverse events were adjudicated by an independent clinical events committee.

Statistical design and statistical analysis

The key efficacy evaluation was based on transthoracic TTE analysis from baseline to device implantation, including the follow-up data. The MACEs and efficacy analyses were performed on those who were discharged from the hospital after being treated with the study device. The following baseline characteristics were summarized using the mean ± standard deviation (SD) for continuous variables and counts and percentages for categorical variables. Paired t-test was conducted to compare the quantitative data; the signed-rank test was applied for the ranked data comparison. All statistical tests were performed using a two-sided test; P ≤ 0.05 was considered statistically significant. All analyses were performed using SPSS 21.0 (USA).

Results

Patient characteristics

From November 2015 to April 2017, 139 patients with post-anterior MI were initially enrolled in our trial (Fig. 1). These patients were screened by 2D TEE and Doppler examinations. A total of 122 of these patients were ineligible, 98 subjects had not developed an aneurysm in the LV, and 24 patients had an LVEF less than 15% or over 40%. Device sizing and anatomical approval were granted by the central CT core lab. Seventeen patients received CT scan for proper PARACHUTE device selection; 11 were excluded for LV false tendons (four subjects), LV thrombosis (two subjects), and not being structurally fit for the device (three subjects); two patients withdrew their consent. Six patients were discharged with the PARACHUTE device and followed up for cardiac function and clinical outcomes. The mean follow-up time was 4.6 ± 1.7 years.

Fig. 1
figure1

Disposition of subjects enrolled. Six post-myocardial infarction eligible subjects with aneurysm received the PARACHUTE device

All the patients must have had a diagnosis of NYHA Class II, III, or IV before enrollment to be included in this study. Ischemic heart disease was present in all patients. All subjects with LV descending artery MI had a prior percutaneous coronary intervention. The average age of the patients was 55.7 ± 11.3 years old, the average time from an acute MI to PARACHUTE implantation was 13.5 ± 12.9 months, and BMI was 26.0 ± 2.0. Three patients had single-vessel occlusion, the rest had multivessel disease, and all revascularization was complete in their first hospitalization (data not shown). Five males and one female were involved. We hospitalized one patient for HF within 12 months. The baseline demographic data are shown in Table 1. All patients had LV post-MI aneurysm, and no patient received ICDs or CRTs.

Table 1 Baseline demographic data

As presented in Table 2, the PARACHUTE devices were implanted through the femoral artery of all the six subjects (Fig. 2a). The procedure was successful in six (100%) patients, without a perforation case. No major vascular complications were found, and no PARACHUTE device was expanded or deployed improperly. In addition, no acute thrombosis and emergent surgery occurred during the procedure.

Table 2 Procedural data
Fig. 2
figure2

Sequence of the PARACHUTE device implantation in the left ventricle. The operation was performed through the femoral artery (a). LV angiography was executed to observe the systolic (b) and diastolic (c) LV geometry. The device was placed in contact within the LV apical wall (d). After balloon inflation to facilitate device expansion, the LV geometric reconfiguration was evaluated in the systolic (e) and diastolic (f) phases. The white dotted line indicates the outline of the chamber morphological characteristics before the device implantation. The white arrow indicates the implanted PARACHUTE device

The procedure of the device implantation is briefly illustrated in Fig. 2. The PARACHUTE device was expanded and implanted in the LV apical wall. LV angiography was performed once again to evaluate the geometry of LV (Fig. 2e and f). As displayed in Fig. 2, LV volume was remarkably reduced in the systole and diastole phases.

Clinical and functional outcomes

Patients in our center were followed up for 4.6 ± 1.7 years. Safety end-points are illustrated in Table 3 and Fig. 3. MACEs occurred in three (50%) patients (Fig. 3a). The most frequently reported MACEs were HF and unplanned interventional therapy. Three subjects (50%) received coronary artery intervention; one of them was diagnosed with non-ST elevation MI, other two have progressive angina attack. Three patients developed HF on the 85th, 418th, and 1599th days. on the 568th day due to progressively worsening HF. The device-related MI and emergent/selective cardiac or aortic surgery were not observed (Table 3).

Table 3 Major adverse cardiac events and medication therapy
Fig. 3
figure3

Cumulative incidence of cardiovascular events in PARACHUTE-implanted patients. a Cumulative event rates for the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or heart failure end-point. b, c, and d Cumulative myocardial infarction, hospitalization, and mortality, respectively. e Changes in functional capacity according to NYHA. MACEs, major adverse cardiovascular events; MI, myocardial infarction; HFH, hospitalization for heart failure. NYHA, New York Heart Association class

Our center observed the successful delivery of the PARACHUTE device through 6 months follow-up without device-related MACEs. The medication therapy of the subjects was consistent from inclusion into the trial up to one-year follow-up. DAPT, Statin, Warfarin, and β-blocker were 100% taken in all patients; ACEI/ARB and spironolactone were 83.3%. Even though all patients received warfarin for more than 12 months, device-related embolization was found in a patient by CT and TTE.

Our center analyzed echocardiographic parameters of these subjects at baseline and each time of follow-up, including the LVEF, LVEDD, and estimated PAP. We collected the baseline data after the first attack of anterior MI. Subsequently, data were obtained before the PARACHUTE device implantation and 1 week, 6 months, 1 ± 0.25 year, 2 ± 0.5 years, and 3 ± 0.5 years after device implantation.

We further performed a per- verse post-implantation pairwise comparison of echocardiography. The results of TTE-based cardiac function assessment are shown in Fig. 4. Compared with the baseline, the LVEF was significantly reduced at the time when patients enrolled in the trial (50.67 ± 0.82% vs. 35.83 ± 1.47%, P < 0.001). PARACHUTE remarkably elevated LV systolic function in 1 week (35.8 ± 1.47% vs. 46.00 ± 6.0%, P = 0.009, illustrated in Fig. 4a and b). For the subjects without MACEs, compared with the one-week measurement, the LVEF demonstrated relatively sustained improvement when we referred to the latest follow-up (42.33 ± 3.51% vs. 43.67 ± 3.06%, P = 0.757). By contrast, patients with MACEs often showed a moderate decline (49.67 ± 6.03% vs. 35.67 ± 4.04%, P = 0.112).

Fig. 4
figure4

Transthoracic echocardiograph-based cardiac function assessment. Transthoracic echocardiography (TTE)-based cardiac function evaluation was performed at baseline (the first time for MI treatment); before the PARACHUTE device procedure; and at 1 week, 6 months, 1 year, 2 years, and 3 years after device implantation. a, c, and e Comparison of each time point for the left ventricular ejection fraction, left ventricular end-diastolic diameter, and estimated pulmonary artery pressure assessment, respectively. b, d, and f Changes in the TTE-based parameter measurement mentioned above. ***: P < 0.001, compared with baseline; ##: P < 0.01, compared with the PARACHUTE procedure; NS: not significant. mm: millimeter

Patients showed a significant chronic increase in LVEDD before the procedure (51.17 ± 3.71% vs.62.83 ± 3.25%, P < 0.001). After the implantation, TTE exhibited no pronounced change in LVEDD, and the progressive LV enlargement was inhibited (Fig. 4c and d). We further measured estimated PAP in Fig. 4e and f, except for the early death of one patient due to HF. The estimated PAP was comparable in each time evaluation.

Notably, the device-related MACEs also contributed to the poor prognosis. Here, we found one case of embolization that may worsen the state of illness (Fig. 5). Figure 5a is an image captured immediately after PARACHUTE implantation. The latest contrast-enhanced CT of the LV (Fig. 5b) showed the occurrence of device-associated embolization. We conducted a 3D TTE and Doppler scan to exclude device migration (Fig. 5c and d). Furthermore, MCE and LVO were employed to confirm the thrombus located in the LV apex (Fig. 5e and f). These results suggested that the patients should continue to receive warfarin to prevent stroke, even though no embolization-associated adverse events are found. Moreover, long-term anticoagulant treatment may help prevent thrombus-related events.

Fig. 5
figure5

Case with left ventricular thrombus after device implantation by contrast echocardiography. a CT scan right after the PARACHUTE implantation to check potential device-related migration or embolization. b Latest follow-up detected by contrast-enhanced CT. The filling defect appeared in the apical left ventricle. c and d 3D-TTE and 2D-TEE were applied to exclude device migration, respectively. The white arrow indicates the implanted device. e and f Left ventricular thrombus confirmed by LVO and MCE, respectively. The white arrow points to the filling defect-implied LV apical thrombus

Discussion

In this study, we demonstrated that PARACHUTE therapy could be beneficial for the maladaptive remodeling of patients with post-MI by restoring LV ejection and suppressing continuous and overwhelmed LV enlargement, thereby improving patients’ long-term prognosis especially in LVEF-sustained preserved subjects. Limited by the size of cohort, the conclusion may not be robust, however, it could be an alternative treatment for specific group of anterior myocardial infarction patients.

Typical LV dilation is common in patients with an anterior infarction [6]. As a consequence of anterior MI, the LV continuously develops geometrically from ellipsoid to spherical [7], accompanied with chamber dilation and wall motion abnormalities. The dilation of LV increased ventricle volume elevates filling pressure, resulting in the enhanced burden of remaining myocytes, progressive subendocardial myocardial ischemia [8], hemodynamic disorder such as functional mitral regurgitation [4], HF, and death [9]. Many studies have proven that LV remodeling is an independent clinical predictor of prognosis in patients with HF [10]. The beneficial effects of drugs or medical devices on LV remodeling have also been associated with reduced long-term mortality [11]. Therefore, effective and safe treatment strategies are urgently needed to restore LV function and improve outcomes of patients with HF.

To exert the maximum benefit effect to HF patients in this trial, restricted heart features were carefully evaluated, false tendons and ventricular thrombosis are the contraindications of the PARACHUTE procedure. Six eligible subjects were enrolled to the study, the cautiously HF patient selection also contribute to procedural safety eventually. The aforementioned studies [4, 12,13,14] suggested that the PARACHUTE device can reduce cardiac dimensions and end-diastolic wall stress and improve cardiac output. However, the three-year results indicated a reduction of LVEF and stroke volume. The PARACHUTE IV trial was terminated due to death or rehospitalization for worsening HF.

The device restored enrolled patients’ LV systolic function, and this result was consistent with the findings of prior studies [4, 5, 13]. LVEF significantly improved from preimplantation to 7 days after deployment (35.83 ± 1.47% vs. 46.00 ± 6.00%, P = 0.009). The LVEDD and estimated PAP were relatively stable, which suggested that this therapy was effective and safe for patients. The improvement in NYHA functional class was also observed in other patients (illustrated in Fig. 3).

Patients with prior MI have a much higher risk to develop HF and multivessel coronary artery disease than their counterparts [15]. The device is designed to prevent maladaptive LV remodeling, which is helpless in inhibiting recurrent coronary attack. Therefore, personalized treatment should be sought to decrease coronary risks. The HF that occurred in half of our enrolled patients may be partly because they selected suffered from severe cardiac remodeling, thereby enhancing the ratio of cardiac adverse events. However, the device-related MACEs also contributed to the poor prognosis.

As this clinical trial previously designed, all patients received low-dose aspirin and anticoagulation with warfarin for at least 12 months of post-device implantation. The duration of antiplatelet or anticoagulation is based on the spontaneous reendothelialization time. Extra anticoagulation is unnecessary when the implants are completely reendothelialized. The concept is also applicable to the PARACHUTE device. In color doppler flow imaging, we observed that blood flow crossed the device, suggesting it was not entirely reendothelialized even after 3 years, so thrombosis may be promoted. The evidence implies that the PARACHUTE device may need to be refined to fit the geometry of the dilated ventricle.

Despite the small number of patients in our center, we have the longest clinical observation of the PARACHUTE cohort in China. In this trial, the efficiency and safety of the PARACHUTE procedure were investigated, and long-term MACE and cardiac function were evaluated. These data add further evidence to PARACHUTE studies and prove that the ventricular partition device is relatively safe and may reduce long-term death. However, the PARACHUTE device could increase the HF ratio.

Limitations

The study was limited by its small sample size; unblinded, single-arm nature; and single-center clinical observations. Given that it was conducted in self-control mode and lacked a control group using standardized medical therapy or SVR, we could not rule out potential bias in the adjudication process. Furthermore, a robust conclusion could not be made without control group efficacy.

Conclusions

The PARACHUTE device is an alternative therapy for patients with severe LV maladaptive remodeling. However, the PARACHUTE device seems to increase the HF ratio at 4.6 years follow-up.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Abbreviations

HF:

Heart failure

LV:

Left ventricular

LVEDD:

LV end-diastolic diameter

ICDs:

Implantable cardioverter defibrillator

CRT-Ds:

Cardiac resynchronization therapy

SVR:

Surgical ventricular reconstruction

NYHA:

New York Heart Association

TTE:

Transthoracic echocardiography

MCE:

Myocardial contrast echocardiography

LVO:

LV opacification

MACEs:

Major adverse cardiac events

PCI:

Percutaneous coronary intervention

CABG:

Coronary artery bypass grafting

PVR:

Percutaneous ventricular restoration

ACEI:

Angiotensin-converting enzyme inhibitors

ARB:

Angiotensin receptor blocker

References

  1. 1.

    Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation. 1993;87(3):755–63. https://doi.org/10.1161/01.CIR.87.3.755.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81(4):1161–72. https://doi.org/10.1161/01.CIR.81.4.1161.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Schmidt T, Frerker C, Thielsen T, Dotz I, Wohlmuth P, Kuck KH, et al. New evidence for favourable effects on haemodynamics and ventricular performance after parachute(®) implantation in humans. Eur J Heart Fail. 2014;16(10):1112–9. https://doi.org/10.1002/ejhf.160.

    Article  PubMed  Google Scholar 

  4. 4.

    Costa MA, Mazzaferri EL Jr, Sievert H, Abraham WT. Percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure: three-year outcomes of the PARACHUTE first-in-human study. Circ Heart Fail. 2014;7(5):752–8. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001127.

    Article  PubMed  Google Scholar 

  5. 5.

    Yang YJ, Huo Y, Xu YW, Wang JA, Han YL, Ge JB, et al. Percutaneous ventricular restoration therapy using the parachute device in Chinese patients with ischemic heart failure: three-month primary end-point results of PARACHUTE China study. Chin Med J. 2016;129(17):2058–62. https://doi.org/10.4103/0366-6999.189048.

    Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Stone PH, Raabe DS, Jaffe AS, Gustafson N, Muller JE, Turi ZG, et al. Prognostic significance of location and type of myocardial infarction: independent adverse outcome associated with anterior location. J Am Coll Cardiol. 1988;11(3):453–63. https://doi.org/10.1016/0735-1097(88)91517-3.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Bhatt AS, Ambrosy AP, Velazquez EJ. Adverse remodeling and reverse remodeling after myocardial infarction. Curr Cardiol Rep. 2017;19(8):71.

    Article  Google Scholar 

  8. 8.

    van den Heuvel AF, van Veldhuisen DJ, van der Wall EE, Blanksma PK, Siebelink HM, Vaalburg WM, et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2000;35(1):19–28. https://doi.org/10.1016/S0735-1097(99)00499-4.

    Article  PubMed  Google Scholar 

  9. 9.

    Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35(3):569–82. https://doi.org/10.1016/S0735-1097(99)00630-0.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging. 2011;4(1):98–108. https://doi.org/10.1016/j.jcmg.2010.10.008.

    Article  PubMed  Google Scholar 

  11. 11.

    Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol. 2010;56(5):392–406. https://doi.org/10.1016/j.jacc.2010.05.011.

    Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Mazzaferri EL Jr, Gradinac S, Sagic D, Otasevic P, Hasan AK, Goff TL, et al. Percutaneous left ventricular partitioning in patients with chronic heart failure and a prior anterior myocardial infarction: Results of the PercutAneous Ventricular RestorAtion in Chronic Heart failUre PaTiEnts Trial. Am Heart J. 2012;163(5):812–20.e1.

    Article  Google Scholar 

  13. 13.

    Thomas M, Nienaber CA, Ince H, Erglis A, Vukcevic V, Schäfer U, et al. Percutaneous ventricular restoration (PVR) therapy using the parachute device in 100 subjects with ischaemic dilated heart failure: one-year primary endpoint results of PARACHUTE III, a European trial. EuroIntervention. 2015;11(6):710–7. https://doi.org/10.4244/EIJV11I6A143.

    Article  PubMed  Google Scholar 

  14. 14.

    Costa MA, Pencina M, Nikolic S, Engels T, Templin B, Abraham WT. The PARACHUTE IV trial design and rationale: percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure and dilated left ventricles. Am Heart J. 2013;165(4):531–6. https://doi.org/10.1016/j.ahj.2012.12.022.

    Article  PubMed  Google Scholar 

  15. 15.

    Sabatine MS, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira J, et al. Clinical benefit of Evolocumab by severity and extent of coronary artery disease: analysis from FOURIER. Circulation. 2018;138(8):756–66. https://doi.org/10.1161/CIRCULATIONAHA.118.034309.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank our colleagues Keqi Chen, Linjie Luo, Juheng Ye, Xinli Pang, Xinjian Liang (Department of Cardiology, Shenzhen People’s Hospital) and Hong Gao (Department of Cardiology, Shenzhen 3rd People’s Hospital) for study support.

Disclosures

None

Funding

This study was supported by the Medical Scientific Research Foundation of Guangdong Province of China (No. A2018530), Sanming Project of Medicine in Shenzhen (No. SZSM201412012), Shenzhen Key Medical Discipline Construction Fund (No. szxk003), Science and Technology Planning Project of Shenzhen Municipality (No. JCYJ20170307100512856) and the National Natural Science Foundation of China (No. 81770496).

Author information

Affiliations

Authors

Contributions

JH Li, SH Dong, W Ma, BW Zhang, and TZM Li contributions to the conception or design of the work, and interpretation of data for the work. JH Li, HD Liu, QY liu, C Liu, and TZM Li contribute to the data acquisition and analysis. JH Li drafting the work and TZM Li revising it for important intellectual content. All authors have read and approve the submission of the manuscript.

Corresponding authors

Correspondence to Shaohong Dong or Tangzhiming Li.

Ethics declarations

Ethics approval and consent to participate

The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Human Ethics Committee of Shenzhen people’s hospital. Written informed consent was obtained from individual participants.

Consent for publication

Not applicable.

Competing interests

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Supplementary Figure 1.

Mandatory use of screening cardiac CT to assure the appropriate inclusion of patients. Anatomical insights into patients are provided to allow mechanistic interpretation of the device performance. (A) Measurement of the height from the apex to the implant landing zone. (B) Extra cardiac function assessment on the basis of TTE evaluation. (C) and (D) Diastolic and systolic measurement parameters, respectively.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Li, J., Liu, H., Liu, Q. et al. Long-term prognosis analysis of PARACHUTE device implantation in patients with ischemic heart failure: a single-center experience of Chinese patients. J Cardiothorac Surg 16, 98 (2021). https://doi.org/10.1186/s13019-021-01484-0

Download citation

Keywords

  • Myocardial infarction
  • Left ventricular systolic function
  • Heart failure
  • Mortality